The federal government's partial ban on flavored vape products went into effect at 12:01 a.m. Thursday, capping a year of backlash, lobbying, and patchwork laws meant to respond to what public health officials consider to be an epidemic of teen vaping.

The efficacy of the ban, however, remains an open question. Juul, by far the leading brand of pod-based e-cigarettes, had already voluntarily removed its flavored products from the market, leaving just menthol and tobacco (the two flavors not affected by the FDA's ban). And, as reported recently by the New York Times, many teens have already moved on to disposable vapes, which are exempt from the federal ban in a major loophole.

Lauren Williams, a Kentucky high-school teacher, told the Times: "Students were telling me that everybody had gone to Puff Bars, which are disposable ... the one we confiscated here this week is Banana Ice. Students are not using Juuls anymore because no one wants menthol or tobacco."

In addition to tobacco and menthol flavors, the ban also has carve-outs for "mods," the more advanced e-cigarettes sold in vape shops. That exemption was intended to mollify the vape-shop industry, which said it faced extinction if those were to be regulated. It is also unclear how the FDA will enforce the ban given that vape products are typically sold in convenience stores, of which there are more than 150,000 in the country, according to the industry's trade group. Most of those stores are not part of larger national chains that could institute company-wide implementation efforts.

The FDA, for its part, says that it will closely monitor the marketplace and has an enforcement plan in place.

The partial federal ban follows several other state bans, including one in New York that was blocked by a state judge last month. And on the first day of the federal ban, the now-outlawed flavored pods were still available on some store shelves in Lower Manhattan ー priced at nearly double the cost of the tobacco flavors.

Share:
More In Business
Biogen Lowers Full-Year Profit Forecast
Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
Stretching Your Dollar: Managing Your Money After Fed Decision
As the country watches the financial situation and monitors decisions from the Federal Reserve, many may be re-evaluating what to do with their money, with interest and mortgage rates at some of the highest levels seen in decades. Mark Hamrick, Washington bureau chief and senior economic analyst with Bankrate, joined Cheddar News to provide tips on your money management as monetary policy continues to change.
Load More